EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of Niraparib/Abiraterone Acetate
It is indicated with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer with BRCA1/2 mutations